Alto Neuroscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ANRO New York 2834 www.altoneuroscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alto Neuroscience, Inc.

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock - Jul 13th, 2026 5:47 am
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? - Jul 2nd, 2026 1:58 pm
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing - May 26th, 2026 11:19 pm
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss - Apr 2nd, 2026 2:10 pm
Sector Update: Health Care Stocks Softer Late Afternoon - Apr 2nd, 2026 1:57 pm
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data - Apr 2nd, 2026 12:36 pm
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - Apr 2nd, 2026 6:20 am
Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement - Mar 23rd, 2026 9:14 am
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207 - Mar 23rd, 2026 6:55 am
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - Mar 11th, 2026 3:31 pm
Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price - Feb 5th, 2026 4:20 am
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company - Dec 26th, 2025 6:36 am
Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? - Nov 14th, 2025 7:40 am
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days - Nov 11th, 2025 6:55 am
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - Nov 10th, 2025 9:21 am
How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99% - Nov 10th, 2025 7:55 am
Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy - Oct 23rd, 2025 10:00 am
Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect? - Oct 23rd, 2025 7:55 am
Alto shares double on plans to speed depression drug’s development - Oct 20th, 2025 8:50 am
Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia - Oct 17th, 2025 7:27 am